An experimental drug, daraxonrasib, has become the first treatment to substantially extend the lives of pancreatic cancer patients in a clinical trial.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
How an ‘Impossible’ Idea Led to a Pancreatic Cancer Breakthrough - The New York Times
Pancreatic Cancer Patients First drug to substantially extend survival
Pancreatic, Lung, Colon Cancers Targets KRAS protein in
Biggest Advance Since Immunotherapy Potential significance
27 Scientists And Doctors Researchers interviewed
3 cancers targeted
Decades research timeline